Phosphate Binder Selection and Management

Introduction to Phosphate Binders

The American Journal of Kidney Diseases recommends the use of calcium-based agents, non-calcium binders, and iron-based binders as phosphate binders in clinical practice 1, 2, 3

Calcium carbonate contains 40% elemental calcium and is the most widely prescribed phosphate binder due to its low cost and proven efficacy, as recommended by the American Journal of Kidney Diseases 4
The American Journal of Kidney Diseases states that calcium carbonate effectively lowers serum phosphorus but causes more hypercalcemic events compared to other binders 2, 3
Long-term use of calcium carbonate is associated with an increased risk of vascular calcification, particularly when total calcium intake exceeds 2,000 mg/day, according to the American Journal of Kidney Diseases 5
The American Journal of Kidney Diseases notes that calcium acetate is more effective at lowering serum phosphorus compared to calcium carbonate and causes fewer hypercalcemic episodes 2, 4

Sevelamer is a calcium- and aluminum-free binder with proven efficacy and safety in children, as studied in 47 pediatric patients, and is recommended by the American Journal of Kidney Diseases 1, 6
The American Journal of Kidney Diseases states that sevelamer attenuates the progression of arterial calcifications compared to calcium-based binders in adults with CKD stages 3-5 1, 6, 7
Lanthanum carbonate is a calcium- and aluminum-free binder with high phosphate affinity and minimal intestinal absorption, as recommended by the American Journal of Kidney Diseases 1, 6

No unique facts are available for iron-based phosphate binders that meet the criteria.

Magnesium carbonate provides equivalent phosphorus control to calcium carbonate, but its use is limited by the need for decreased magnesium concentration in dialysate, as noted by the American Journal of Kidney Diseases 2, 3

Aluminum-based binders should be avoided except as short-term rescue therapy for severe hyperphosphatemia due to proven toxicity, as recommended by the American Journal of Kidney Diseases 3, 5

The American Journal of Kidney Diseases recommends a clinical decision algorithm for selecting a phosphate binder, including first-line use of calcium-based binders and switching to non-calcium binders when necessary 2, 4, 5
The algorithm suggests adding sevelamer to calcium-based binder for persistent hyperphosphatemia, allowing better phosphorus control while limiting calcium load, as recommended by the American Journal of Kidney Diseases 5

The American Journal of Kidney Diseases notes that non-adherence is the biggest challenge to phosphate binder efficacy, and that calcium citrate should be avoided in CKD patients as it enhances calcium absorption more than other calcium salts 4
Phosphate binders must be taken 10-15 minutes before or during meals to maximize phosphate binding and minimize free calcium absorption, as recommended by the American Journal of Kidney Diseases 4
Dietary phosphate restriction alone is insufficient, and urinary phosphorus excretion does not decrease and may increase by 50% over 2 years despite a low-phosphorus diet, as noted by the American Journal of Kidney Diseases 1, 6, 7